/ /

  • linkedin
  • Increase Font
  • Sharebar

    Safe contraception for women with medical conditions



    1. Food and Drug Administration. Labeling for prescription drugs used in man. Fed Regist. 1975;40:15392–15399.

    2. Food and Drug Administration. Guidance for industry and review staff: labeling for human prescription drug and biological products—determining established pharmacologic class for use in the highlights of prescribing information 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM186607.pdf. Accessed September 29, 2015.

    3. Grossman D, Ellertson C, Abuabara K, Blanchard K, Rivas FT. Barriers to contraceptive use in product labeling and practice guidelines. Am J Public Health. 2006;96(5):791–799.

    4. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2016. MMRW. 2016;65(3):1–104.

    5. The American College of Obstetricians and Gynecologists. Committee opinion no. 505: understanding and using the U.S. Medical Eligibility Criteria For Contraceptive Use, 2010. Obstet Gynecol. 2011:118(3):754–760.

    6. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(No. RR-4):1–66.

    7. Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Women’s Health (London, England). 2013;9(5):453–466.

    8. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol. 2012;120(1):21–6.

    9. Lopez LMGrimes DAChen MOtterness CWesthoff CEdelman AHelmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2013;4:CD008452.

    10. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269–275.

    11. Curtis K, Ravi A, Gaffield M. Progestogen-only contraceptive use in obese women. Contraception. 2009;80(4):346–354.

    12. Westhoff CL, Torgal AH, Maveda ER, Stanczyk FZ, Lerner J, Benn E, Paik M. Ovarian suppression in normal-weight and obese women during oral contraceptive use. Obstet Gynecol. 2010;116(2):275–283.

    13. Yamazaki M, Dwyer K, Sobhan M, et al. Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis. Contraception. 2015;92(5):445–452.

    14. Zieman M, Guillebaud J, Weisberg E, Shangold G. Fisher AC, Creasy G. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system; the analysis of pooled data. Fertil Steril. 2002;77(2):S13–18.

    15. Shaw K, Edelman A. Obesity and oral contraceptives: a clinician’s guide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):55–65.

    16. Chen BA, Reeves MF, Creinin MD, Schwarz EB. Postplacental or delayed levonorgestrel intrauterine device insertion and breastfeeding duration. Contraception. 2011;84(5):499–504.

    17. Dahlke JD, Terpstra ER, Ramseyer AM, Busch JM, Rieg T, Magann EF. Postpartum insertion of levonorgestrel-intrauterine system at three time periods: a prospective randomized pilot study. Contraception. 2011;84(3):244–248.

    18. Shaamsh AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception. 2005;72:346–351.

    19. American College of Obstetricians and Gynecologists. Immediate postpartum long-acting reversible contraception. Committee Opinion No. 670. Obstet Gynecol 2016; 128:e32–7.

    20. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Siva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception. 2009;80(6):519–526.

    21. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant. Obstet Gynecol. 2011;117(5):1114–1121.

    22. Bhardwaj N, Espey E. Lactation and Contraception. Curr Opin Obstet Gynecol. 2015;27:496–503.

    23. Centers for Disease Control and Prevention. Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Hormonal Contraception Methods During the Postpartum Period. MMWR Morb Mortal Wkly Rep. 2011;60(26):878–883.

    24. Espey E, Ogburn T, Leeman L, Singh R, Ostrom K, Scrader R. Effect of progestin compared with combined oral contraceptive pills on lactation: a randomized controlled trial. Obstet Gynecol. 2012;119(1):5–13.

    25. Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol. 2011;117(3):691–703.

    26. Tepper NK, Boulet SL, Whiteman MK, Monsour M, Marchbanks PA, Hooper WC, Curtis KM. Postpartum venous thromboembolism: incidence and risk factors. Obstet Gynecol. 2014;123(5):987–996.

    27. Jackson, E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol. 2011;117(3):657–662.

    28. Speroff L, Mishell DR, The postpartum visit: it’s time for a change in order to optimally initiated contraception. Contraception. 2008;78(2):90–98.

    29. The American College of Obstetricians and Gynecologists. Long-Acting Reversible Contraception Program: Coding and Reimbursement, 2016, http://www.acog.org/About-ACOG/ACOG-Departments/Long-Acting-Reversible-C.... Accessed September 9, 2016.

    30. Centers for Medicare and Medicaid Services. State Medicaid Payment Approaches to Improve Access to Long-Acting Reversible Contraception. Department of Health and Human Services, 8 April 2016, https://www.medicaid.gov/federal-policy-guidance/downloads/CIB040816.pdf. Accessed September 9, 2016.

    31. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125(3):599–604.

    32. The American College of Obstetricians and Gynecologists. Practice Bulletin No. 152: Emergency Contraception. Obstet Gynecol. 2015;126(3):e1-e11.

    33. Abraham M, Zhao Q, Peipert JF. Young age, nulliparity and continuation of long-acting reversible contraceptive methods. Obstet Gynecol. 2015;126(4):823–829.

    34. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69:407–412.

    35. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561–567.

    36. International Headache Society. IHS Classification ICHD-II. http://ihs-classification.org/en/02_klassifikation/02_teil1/01.02.00_migraine.html. Accessed August 30, 2015.

    37. Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. Rev Obstet Gynecol. 2010;3(2):55–65.

    38. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–788.

    39. Walsh T, Grimes D, Frezieres R, et al. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet. 1998; 351(9108):1005–1008.

    40. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012;120(6):1314–1321.

    41. Centers for Disease Control and Prevention. Sexually Transmitted Diseases (STDs). STD and HIV Screening Recommendations, 2014. http://www.cdc.gov/std/prevention/screeningreccs.htm Accessed September 1, 2015.


    Neena T Qasba, MD
    Dr Qasba is Family Planning Fellow, Department of Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine, New ...
    Nancy L. Stanwood, MD, MPH
    Dr. Stanwood is Section Chief, Family Planning, and Director, Fellowship in Family Planning, Department of Obstetrics, Gynecology & ...

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • UBM User
      As an accredited Fertility Educator with Natural Fertility NZ and their Clinical Supervisor it is a real disappointment to see that LAM (lactational amenorrhoea method) was not mentioned or investigated as a valid option for client 1. It has no side effects to the mother or baby and actually promotes breastfeeding.


    Latest Tweets Follow